Rituximab for Pulmonary Sarcoidosis

Part of paid clinical trials in Cincinnati, Ohio.

Sponsor
University of Cincinnati
Study ID
NCT00855205
Phase
PHASE2
Status
Completed

Conditions

  • Sarcoidosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Rituximab — DRUG
    Rituximab will be administered by IV infusion at a dose of 1000 mg (1 g) on day 1 and 15

Study Details

Sarcoidosis is a inflammatory disease affecting many parts of the body, especially the lungs. While most patients do well, there is a group of patients who require continuous doses of prednisone or other drugs. The current study will determine the role of Rituximab as new agent for patients with refractory disease.

Key Dates

Start date
Jul 31, 2009
Status verified
Dec 2013
Primary completion
Dec 31, 2012
Completion
Dec 31, 2012

Study Design

Enrollment
10 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment
    Treatment with rituximab

Primary Outcome Measure

Adverse events by week 24 and by week 52 that are considered by the investigator to be reasonably or probably related to Rituximab. [ Time Frame: 1 year ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of CincinnatiCincinnatiOhio45267-

Find similar trials in Cincinnati, OH

By research site
University of Cincinnati· Cincinnati, OH

Related Studies